东瑞制药2023 年报

Corporate Information公司資料 Group Structure本集團架構圖 Chairman’s Statement主席報告 Management Discussion and Analysis管理層討論及分析 Corporate Governance Report企業管治報告 Directors’ and Senior Management’s Biographies董事及高級管理層履歷 Report of the Directors董事會報告 Independent Auditor’s Report獨立核數師報告 Consolidated Statement of Comprehensive Income綜合全面收益表 Consolidated Statement of Financial Position綜合財務狀況表 Consolidated Statement of Changes in Equity綜合權益變動表 Consolidated Statement of Cash Flows綜合現金流量表 Notes to Financial Statements財務報表附註 Five Year Financial Summary五年財務概要 Information for Shareholders股東資料 BOARD OF DIRECTORS 董事會 EXECUTIVE DIRECTORSMs. LI Kei Ling(Chairman)Mr. HUNG Yung Lai 李其玲女士（主席）熊融禮先生 NON-EXECUTIVE DIRECTORMr. LEUNG Hong Man 梁康民先生 勞同聲先生EDE, Ronald Hao Xi先生林明儀女士 INDEPENDENT NON-EXECUTIVE DIRECTORS Mr. LO Tung Sing TonyMr. EDE, Ronald Hao XiMs. LAM Ming Yee Joan CHIEF EXECUTIVE OFFICER 總裁 吳偉賢先生 Mr. WU Weixian 審核委員會 AUDIT COMMITTEE Mr. LO Tung Sing Tony(Chairman)Mr. EDE, Ronald Hao XiMs. LAM Ming Yee Joan 勞同聲先生（主席）EDE, Ronald Hao Xi先生林明儀女士 薪酬委員會 REMUNERATION COMMITTEE Mr. EDE, Ronald Hao Xi(Chairman)Ms. LI Kei LingMr. LO Tung Sing TonyMs. LAM Ming Yee Joan EDE, Ronald Hao Xi先生（主席）李其玲女士勞同聲先生林明儀女士 提名委員會 NOMINATION COMMITTEE Ms. LI Kei Ling(Chairman)Mr. LO Tung Sing TonyMr. EDE, Ronald Hao XiMs. LAM Ming Yee Joan 李其玲女士（主席）勞同聲先生EDE, Ronald Hao Xi先生林明儀女士 AUDITORS 核數師 Ernst & YoungCertified Public AccountantsRegistered Public Interest Entity Auditor 安永會計師事務所執業會計師註冊公眾利益實體核數師 主要往來銀行 PRINCIPAL BANKERS Bank of China (Hong Kong) Limited, Hong KongThe Hongkong and Shanghai Banking Corporation Limited, Hong KongIndustrial and Commercial Bank of China Suzhou Wuzhong Sub-BranchAgricultural Bank of China Suzhou Nanmen Sub-BranchBank of China Suzhou Wuzhong Sub-Branch 中國銀行（香港）有限公司，香港香港上海滙豐銀行有限公司，香港中國工商銀行蘇州市吳中支行中國農業銀行蘇州市南門支行中國銀行蘇州吳中支行 HEAD OFFICE AND PRINCIPAL PLACE OF BUSINESS 總辦事處及主要營業地點 Units 3001–02, 30/F, CNT Tower, 338 Hennessy Road,Wanchai, Hong Kong 香港灣仔軒尼詩道338號北海中心30樓3001–02室 註冊辦事處 REGISTERED OFFICE Cricket SquareHutchins DriveP.O. Box 2681Grand Cayman KY1-1111Cayman Islands Cricket SquareHutchins DriveP.O. Box 2681Grand Cayman KY1-1111Cayman Islands 主要股份過戶登記處 PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE Conyers Trust Company (Cayman) LimitedCricket Square, Hutchins Drive, P.O. Box 2681,Grand Cayman KY1-1111, Cayman Islands Conyers Trust Company (Cayman) LimitedCricket Square, Hutchins Drive, P.O. Box 2681,Grand Cayman KY1-1111, Cayman Islands 香港股份過戶登記分處 HONG KONG BRANCH SHARE REGISTRAR ANDTRANSFER OFFICE 卓佳雅柏勤有限公司香港夏慤道16號遠東金融中心17樓 Tricor Abacus Limited17/F, Far East Finance Centre,16 Harcourt Road, Hong Kong Group Structure As at 22 March 2024於二零二四年三月二十二日 GROUP RESULTS 本集團業績 For the year ended 31 December 2023, the Group recorded revenue ofapproximately RMB1,151,145,000 (2022: RMB1,277,682,000),representing a decrease of 9.9% as compared with 2022. Profitattributable to owners of the parent was approximately RMB326,000,000(2022: RMB358,057,000), representing a decrease of 9.0% as comparedwith 2022. 本集團截至二零二三年十二月三十一日止年度錄得收入約人民幣1,151,145,000元（二零二二年：人民幣1,277,682,000元），較二零二二年減少約9.9%。母公司擁有人應佔溢利約人民幣326,000,000元（二零二二年：人民幣358,057,000元），比二零二二年下降約9.0%。 母公司擁有人應佔溢利含本集團天靈路搬遷處置資產淨收益人民幣118,858,000元、投資於聯營公司康融 東 方（ 廣 東 ）醫 藥 有 限 公 司 承 擔 之 虧 損 人 民 幣40,933,000元（二零二二年：人民幣61,905,000元），及清算本集團附屬公司東瑞（南通）醫藥科技有限公司（「東瑞南通」）之匯兌虧損人民幣1,879,000元非經常性項目，如撇除以上因素，經營性溢利為人民幣249,954,000元（ 二 零 二 二 年： 人 民 幣380,292,000元），較二零二二年下跌34.3%。主要是受到項目搬遷及產品集採丟標影響銷售收入減少及增加生產成本，加上新建研究院及蘭州東瑞致使行政費用及研發費用有所增加所致。 Profit attributable to owners of the parent included a net gain ofRMB118,858,000 on the disposal of the assets arising from the relocationGroup’s factory on Tianling Road, a loss of RMB40,933,000 on theinvestment in AD Pharmaceuticals Co., Ltd., an associated company(2022: RMB61,905,000), and a non-recurring item, which is the exchangeloss of RMB1,879,000 from the liquidation of Dawnrays (Nantong)Pharmaceutical Science and Technology Co., Ltd. (“Dawnrays (Nantong)”).If the above factors are excluded, the operating profit would beRMB249,954,000 (2022: RMB380,292,000), representing a decrease of34.3% as compared with 2022. This was mainly attributable to the impacton the decrease in sales revenue and the rise in production costs resultingfrom project relocation and loss of bids for centralized procurementproducts, as well as the increase in administrative expenses and researchand development costs due to the newly established research institute andLanzhou Dawnrays. FINAL DIVIDEND 末期股息 The Board recommends the payment of a final dividend of HK$0.065 pershare for the year ended 31 December 2023 (2022: HK$0.073), totalingapproximately HK$97,516,000 (2022: approximately HK$109,412,000)(equivalent to approximately RMB89,670,000 (2022: approximatelyRMB95,975,000)), to the shareholders whose names appeared in theregister of members on Friday, 31 May 2024 subject to the approval of theshareholders at the forthcoming 2024